{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimers disease (AD)", "Parkinsons disease (PD)", "cannabinoids", "endocannabinoids", "inflammation", "multiple sclerosis (MS)"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36637897", "DateCompleted": {"Year": "2023", "Month": "06", "Day": "08"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "13"}], "Language": ["eng"], "ELocationID": ["10.1002/biof.1936"], "Journal": {"ISSN": "1872-8081", "JournalIssue": {"Volume": "49", "Issue": "3", "PubDate": {"Year": "2023", "Season": "May-Jun"}}, "Title": "BioFactors (Oxford, England)", "ISOAbbreviation": "Biofactors"}, "ArticleTitle": "Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases.", "Pagination": {"StartPage": "560", "EndPage": "583", "MedlinePgn": "560-583"}, "Abstract": {"AbstractText": ["The medicinal properties of cannabis and cannabinoid-derivative are entirely investigated and known. In addition, the identification of psychotropic plant cannabinoids has led to more studies regarding the cannabinoid system and its therapeutic features in the treatment and management of clinical symptoms of neuroinflammatory disorders, such as multiple sclerosis (MS), Parkinsons disease (PD), and Alzheimers disease (AD). In fact, cannabinoid agonists are able to control and regulate inflammatory responses. In contrast to the cannabinoid receptor type 1 (CB1) and its unwanted adverse effects, the cannabinoid receptor type 2 (CB2) and its ligands hold promise for new and effective therapeutic approaches. So far, some successes have been achieved in this field. This review will discuss an outline of the endocannabinoid system's involvement in neuroinflammatory disorders. Moreover, the pharmacological efficacy of different natural and synthetic preparations of phytocannabinoids acting on cannabinoid receptors, particularly in MS, PD, and AD, will be updated. Also, the reasons for targeting CB2 for neurodegeneration will be explained."], "CopyrightInformation": "\u00a9 2023 International Union of Biochemistry and Molecular Biology."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Immunology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran."}], "LastName": "Abd-Nikfarjam", "ForeName": "Bahareh", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Dolati-Somarin", "ForeName": "Amirhossein", "Initials": "A"}, {"Identifier": ["0000-0003-2320-5095"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Baradaran Rahimi", "ForeName": "Vafa", "Initials": "V"}, {"Identifier": ["0000-0001-9268-6270"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Askari", "ForeName": "Vahid Reza", "Initials": "VR"}], "GrantList": [{"Agency": "Mashhad University of Medical Sciences", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Biofactors", "NlmUniqueID": "8807441", "ISSNLinking": "0951-6433"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Endocannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Cannabinoid"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use", "pharmacology"], "DescriptorName": "Cannabinoids"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Multiple Sclerosis"}, {"QualifierName": [], "DescriptorName": "Neuroinflammatory Diseases"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Parkinson Disease"}, {"QualifierName": [], "DescriptorName": "Endocannabinoids"}, {"QualifierName": [], "DescriptorName": "Receptors, Cannabinoid"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "McKenna M, McDougall JJ. Cannabinoid control of neurogenic inflammation. Br J Pharmacol. 2020;177:4386-99."}, {"Citation": "Russo EB, Marcu J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol. 2017;80:67-134."}, {"Citation": "Navarrete C, Garcia-Martin A, DeMesa J, Mu\u00f1oz E. Cannabinoids in metabolic syndrome and cardiac fibrosis. Curr Hypertens Rep. 2020;22:1-10."}, {"Citation": "Joshi N, Onaivi ES. Endocannabinoid system components: overview and tissue distribution. Adv Exp Med Biol. 2019;1162:1-12."}, {"Citation": "Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G, Memo M, et al. Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Horm Mol Biol Clin Invest. 2018;36:20180013."}, {"Citation": "Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 2007;5:73-80."}, {"Citation": "Askari VR, Baradaran Rahimi V, Tabatabaee SA, Shafiee-Nick R. Combination of imipramine, a sphingomyelinase inhibitor, and beta-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol. 2019;77:105923."}, {"Citation": "Askari VR, Shafiee-Nick R. The protective effects of beta-caryophyllene on LPS-induced primary microglia M(1)/M(2) imbalance: a mechanistic evaluation. Life Sci. 2019;219:40-73."}, {"Citation": "Askari VR, Shafiee-Nick R. Promising neuroprotective effects of \u03b2-caryophyllene against LPS-induced oligodendrocyte toxicity: a mechanistic study. Biochem Pharmacol. 2019;159:154-71."}, {"Citation": "Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20:10-4."}, {"Citation": "Alexander SP, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, et al. The concise guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. Br J Pharmacol. 2019;176:S21-S141."}, {"Citation": "Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19:833."}, {"Citation": "Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17:1468-86."}, {"Citation": "Chen D-J, Gao M, Gao F-F, Su Q-X, Wu J. Brain cannabinoid receptor 2: expression, function and modulation. Acta Pharmacol Sin. 2017;38:312-6."}, {"Citation": "Miller A, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol. 2008;153:299-308."}, {"Citation": "Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res. 2011;51:26-38."}, {"Citation": "Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17:623-39."}, {"Citation": "Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012;367:3353-63."}, {"Citation": "Baradaran Rahimi V, Askari VR. A mechanistic review on immunomodulatory effects of selective type two cannabinoid receptor beta-caryophyllene. Biofactors. 2022;48:857-82."}, {"Citation": "Guerrero-Alba R, Barrag\u00e1n-Iglesias P, Gonz\u00e1lez-Hern\u00e1ndez A, Valdez-Mor\u00e1les EE, Granados-Soto V, Cond\u00e9s-Lara M, et al. Some prospective alternatives for treating pain: the endocannabinoid system and its putative receptors GPR18 and GPR55. Front Pharmacol. 2019;9:1496."}, {"Citation": "Vemuri VK, Makriyannis A. Medicinal chemistry of cannabinoids. Clin Pharmacol Therapeut. 2015;97:553-8."}, {"Citation": "Devane WA, Hanu\u0161 L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-9."}, {"Citation": "De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009;23:1-15."}, {"Citation": "Rahimi VB, Rajabian A, Rajabi H, Vosough EM, Mirkarimi HR, Hasanpour M, et al. The effects of hydro-ethanolic extract of Capparis spinosa (C. spinosa) on lipopolysaccharide (LPS)-induced inflammation and cognitive impairment: evidence from in vivo and in vitro studies. J Ethnopharmacol. 2020;256:112706."}, {"Citation": "Jones \u00c9, Vlachou S. A critical review of the role of the cannabinoid compounds \u03949-tetrahydrocannabinol (\u03949-THC) and cannabidiol (CBD) and their combination in multiple sclerosis treatment. Molecules. 2020;25:4930."}, {"Citation": "Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16:9-29."}, {"Citation": "Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Phytocannabinoids. 2017;103-31."}, {"Citation": "Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol. 2013;8:608-20."}, {"Citation": "Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333-49."}, {"Citation": "Mecha M, Feli\u00fa A, Carrillo-Salinas F, Rueda-Zubiaurre A, Ortega-Guti\u00e9rrez S, de Sola RG, et al. Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 2015;49:233-45."}, {"Citation": "Cabral G, Raborn E, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153:240-51."}, {"Citation": "S\u00e1nchez A, Garcia-Merino A. Neuroprotective agents: cannabinoids. Clin Immunol. 2012;142:57-67."}, {"Citation": "Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400-11."}, {"Citation": "Vrechi TA, Crunfli F, Costa AP, Torr\u00e3o AS. Cannabinoid receptor type 1 agonist ACEA protects neurons from death and attenuates endoplasmic reticulum stress-related apoptotic pathway signaling. Neurotox Res. 2018;33:846-55."}, {"Citation": "Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011;334:809-13."}, {"Citation": "Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84-8."}, {"Citation": "Ronco AM, Llanos M, Tamayo D, Hirsch S. Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid. Pharmacology. 2007;79:12-6."}, {"Citation": "Panikashvili D, Na'ama AS, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006;22:257-64."}, {"Citation": "Rahman RM, Nair SM, Appleton I. Current and future pharmacological interventions for the acute treatment of ischaemic stroke. Curr Anaesth Crit Care. 2005;16:99-109."}, {"Citation": "Clarkson AN, Rahman R, Appleton I. Inflammation and autoimmunity as a central theme in neurodegenerative disorders: fact or fiction? Curr Opin Investig Drugs. 2004;5:706-13."}, {"Citation": "Smith PF. GW-1000. GW pharmaceuticals. Curr Opin Investig Drugs. 2004;5:748-54."}, {"Citation": "Smith PF. Will medicinal cannabinoids prove to be useful clinically? Current Drug Therapy. 2007;2:143-50."}, {"Citation": "Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281:36569-78."}, {"Citation": "Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, et al. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol. 2006;26:405-21."}, {"Citation": "Huffman J. CB2 receptor ligands. Mini Rev Med Chem. 2005;5:641-9."}, {"Citation": "Yao B, Mukherjee S, Fan Y, Garrison T, Daza A, Grayson G, et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol. 2006;149:145-54."}, {"Citation": "Hevner RF, Hodge RD, Daza RA, Englund C. Transcription factors in glutamatergic neurogenesis: conserved programs in neocortex, cerebellum, and adult hippocampus. Neurosci Res. 2006;55:223-33."}, {"Citation": "Raduner S, Majewska A, Chen J-Z, Xie X-Q, Hamon J, Faller B, et al. Alkylamides from Echinacea are a new class of cannabinomimetics: cannabinoid type 2 receptor-dependent and-independent immunomodulatory effects. J Biol Chem. 2006;281:14192-206."}, {"Citation": "Teixeira-Clerc F, Julien B, Grenard P, Van Nhieu JT, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006;12:671-6."}, {"Citation": "McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002;100:627-34."}, {"Citation": "Schwartz M, Butovsky O, Br\u00fcck W, Hanisch U-K. Microglial phenotype: is the commitment reversible? Trends Neurosci. 2006;29:68-74."}, {"Citation": "Cabral G, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol. 2005;78:1192-7."}, {"Citation": "Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18:1-10."}, {"Citation": "Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front Immunol. 2018;9:1782."}, {"Citation": "Gonz\u00e1lez-Garc\u00eda C, Torres IM, Garc\u00eda-Hern\u00e1ndez R, Campos-Ru\u00edz L, Esparragoza LR, Coronado MJ, et al. Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. Exp Neurol. 2017;298:57-67."}, {"Citation": "Nichols JM, Kummari E, Sherman J, Yang E-J, Dhital S, Gilfeather C, et al. CBD suppression of EAE is correlated with early inhibition of splenic IFN-\u03b3+ CD8+ T cells and modest inhibition of neuroinflammation. J Neuroimmune Pharmacol. 2021;16:346-62."}, {"Citation": "Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011;163:1507-19."}, {"Citation": "Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N. Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience. 2015;290:279-87."}, {"Citation": "Hilliard A, Stott C, Wright S, Guy G, Pryce G, Al-Izki S, et al. Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis. Int Scholarly Research Notices. 2012;2012:802649."}, {"Citation": "Moreno-Martet M, Feli\u00fa A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fern\u00e1ndez-Ruiz J, et al. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to \u03949-tetrahydrocannabinol acting through CB1 receptors. Mult Scler Relat Disord. 2015;4:505-11."}, {"Citation": "Al-Ghezi ZZ, Busbee PB, Alghetaa H, Nagarkatti PS, Nagarkatti M. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav Immun. 2019;82:25-35."}, {"Citation": "Sheean G. The pathophysiology of spasticity. Eur J Neurol. 2002;9:3-9."}, {"Citation": "Zhou T, Ahmad TK, Alrushaid S, Pozdirca M, Ethans K, Intrater H, et al. Therapeutic impact of orally administered cannabinoid oil extracts in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Biochem Biophys Res Commun. 2019;516:373-80."}, {"Citation": "Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J r, Chicca A. Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. ACS Pharmacol Translational Sci. 2021;4:765-79."}, {"Citation": "Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, et al. Pain modulation after oromucosal cannabinoid spray (SATIVEX\u00ae) in patients with multiple sclerosis: a study with quantitative sensory testing and laser-evoked potentials. Medicines. 2018;5:59."}, {"Citation": "Manterola A, Bernal-Chico A, Cipriani R, Canedo-Antelo M, Moreno-Garc\u00eda \u00c1, Mart\u00edn-Fontecha M, et al. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. Biochem Pharmacol. 2018;157:189-201."}, {"Citation": "Ujv\u00e1ry I, Hanu\u0161 L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1:90-101."}, {"Citation": "Markov\u00e0 J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, et al. Sativex\u00ae as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129:119-28."}, {"Citation": "Clark A, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62:2098-100."}, {"Citation": "Fife TD, Moawad H, Moschonas C, Shepard K, Hammond N. Clinical perspectives on medical marijuana (cannabis) for neurologic disorders. Neurology: clinical. Practice. 2015;5:344-51."}, {"Citation": "Gado F, Digiacomo M, Macchia M, Bertini S, Manera C. Traditional uses of cannabinoids and new perspectives in the treatment of multiple sclerosis. Medicines. 2018;5:91."}, {"Citation": "Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler J. 2004;10:434-41."}, {"Citation": "Wade DT, Makela P, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler J. 2006;12:639-45."}, {"Citation": "Collin C, Davies P, Mutiboko I, Ratcliffe S, S. S. i. M. S. Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14:290-6."}, {"Citation": "Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451-9."}, {"Citation": "Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols*(Sativex\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122-31."}, {"Citation": "Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, M. R. Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-32."}, {"Citation": "Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex\u00ae) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71:271-9."}, {"Citation": "Trojano M, Vila C. Effectiveness and tolerability of THC/CBD oromucosal spray for multiple sclerosis spasticity in Italy: first data from a large observational study. Eur Neurol. 2015;74:178-85."}, {"Citation": "Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization. AAPS J. 2021;23:1-9."}, {"Citation": "Killestein J, Hoogervorst E, Reif M, Kalkers N, Van Loenen A, Staats P, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58:1404-7."}, {"Citation": "Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet. 2003;362:1517-26."}, {"Citation": "Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253."}, {"Citation": "Zajicek JP, Sanders H, Wright D, Vickery P, Ingram W, Reilly S, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-9."}, {"Citation": "Freeman R, Adekanmi O, Waterfield M, Waterfield A, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J. 2006;17:636-41."}, {"Citation": "Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. The Lancet Neurology. 2013;12:857-65."}, {"Citation": "Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003."}, {"Citation": "Amar MB. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1-25."}, {"Citation": "Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007;1:CD005029."}, {"Citation": "Rog DJ NT, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29:2068-79."}, {"Citation": "Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. Cmaj. 2008;178:1669-78."}, {"Citation": "Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs. 2010;70:2409-38."}, {"Citation": "Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals. 2012;5:529-52."}, {"Citation": "Jawahar R, Oh U, Yang S, Lapane KL. A systematic review of pharmacological pain management in multiple sclerosis. Drugs. 2013;73:1711-22."}, {"Citation": "Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development Subcommittee of the American Academy of neurology. Neurology. 2014;82:1556-63."}, {"Citation": "Andrzejewski K, Barbano R, Mink J. Cannabinoids in the treatment of movement disorders: a systematic review of case series and clinical trials. Basal Ganglia. 2016;6:173-81."}, {"Citation": "Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 2018;18:1-12."}, {"Citation": "Martyn C, Illis L, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet. 1995;345:579-9."}, {"Citation": "Wissel J, Haydn T, M\u00fcller J, Brenneis C, Berger T, Poewe W, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J Neurol. 2006;253:1337-41."}, {"Citation": "Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16:149-59."}, {"Citation": "Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-73."}, {"Citation": "Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234-46."}, {"Citation": "R. Dutta (2021) Endocannabinoidome and its role in neurological disorders-A comprehensive update of existing literature."}, {"Citation": "Mecha M, Yanguas-Cas\u00e1s N, Feli\u00fa A, Mestre L, Carrillo-Salinas F, Azcoitia I, et al. The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia. Brain Behav Immun. 2019;77:110-26."}, {"Citation": "Giacoppo S, Bramanti P, Mazzon E. Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord. 2017;17:22-31."}, {"Citation": "Russo M, Calabr\u00f2 RS, Naro A, Sessa E, Rifici C, D'Aleo G, et al. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast. 2015;2015:2015-6."}, {"Citation": "Carotenuto A, Iodice R, Petracca M, Inglese M, Cerillo I, Cocozza S, et al. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex\u00ae. Acta Neurol Scand. 2017;135:442-8."}, {"Citation": "Sorosina M, Clarelli F, Ferr\u00e8 L, Osiceanu A, Unal N, Mascia E, et al. Clinical response to nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018;25:934-e970."}, {"Citation": "Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-\u03b21a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016;13:428-38."}, {"Citation": "Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-9."}, {"Citation": "Kavia R, De Ridder D, Constantinescu C, Stott C, Fowler C. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler J. 2010;16:1349-59."}, {"Citation": "Langford R, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260:984-97."}, {"Citation": "Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:1-6."}, {"Citation": "Keating GM. Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex\u00ae): a review in multiple sclerosis-related spasticity. Drugs. 2017;77:563-74."}, {"Citation": "L. Leocani, A. Nuara, E. Houdayer, U. Del Carro, L. Straffi, V. Martinelli, P. Rossi, I. Schiavetti, S. Amadio, M. P. Sormani in: Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS-European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, (2014)."}, {"Citation": "Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland for Sherwood. Neely and Jones; 1817."}, {"Citation": "De Rijk MC, Rocca W, Anderson D, Melcon M, Breteler M, Maraganore D. A population perspective on diagnostic criteria for Parkinson's disease. Neurology. 1997;48:1277-81."}, {"Citation": "Balestrino R, Schapira A. Parkinson disease. Eur J Neurol. 2020;27:27-42."}, {"Citation": "Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem. Neurol Clin. 2013;31:S1-S16."}, {"Citation": "Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson's disease. Front Neuroendocrinol. 2014;35:370-84."}, {"Citation": "Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin. 2016;34:955-65."}, {"Citation": "Goldman SM, Marek K, Ottman R, Meng C, Comyns K, Chan P, et al. Concordance for Parkinson's disease in twins: a 20-year update. Ann Neurol. 2019;85:600-5."}, {"Citation": "Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. \u03b1-Synuclein in Lewy bodies. Nature. 1997;388:839-40."}, {"Citation": "Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol. 2013;47:495-508."}, {"Citation": "Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. \u03b1-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 2000;157:401-10."}, {"Citation": "Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric \u03b1-synuclein bind to the S6\u2032 proteasomal protein and inhibit proteasomal function. J Biol Chem. 2003;278:11753-9."}, {"Citation": "Alim MA, Ma Q-L, Takeda K, Aizawa T, Matsubara M, Nakamura M, et al. Demonstration of a role for \u03b1-synuclein as a functional microtubule-associated protein. J Alzheimers Dis. 2004;6:435-42."}, {"Citation": "Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of \u03b1-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27:9220-32."}, {"Citation": "Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in \u03b1-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083-95."}, {"Citation": "Marsden C. Parkinsons-disease. Lancet. 1990;335:948-52."}, {"Citation": "Brundin P, Ma J, Kordower JH. How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol. 2016;29:459-66."}, {"Citation": "Carroll C, Bain P, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63:1245-50."}, {"Citation": "Mesnage V, Houeto J, Bonnet A, Clavier I, Arnulf I, Cattelin F, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol. 2004;27:108-10."}, {"Citation": "Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28:1088-98."}, {"Citation": "Sieradzan K, Fox S, Hill M, Dick J, Crossman A, Brotchie J. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 2001;57:2108-11."}, {"Citation": "de Faria SM, de Morais Fabr\u00edcio D, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson's disease. J Psychopharmacol. 2020;34:189-96."}, {"Citation": "Querfurth HW, LaFerla FM. Mechanisms of disease. N Engl J Med. 2010;362:329-44."}, {"Citation": "Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27:1-13."}, {"Citation": "Fratiglioni L, De Ronchi D, Ag\u00fcero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-75."}, {"Citation": "Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995;273:1354-9."}, {"Citation": "Zhu CW, Sano M. Economic considerations in the management of Alzheimer's disease. Clin Interv Aging. 2006;1:143-54."}, {"Citation": "Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Disease-a-month: DM. 2010;56:484-546."}, {"Citation": "Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-90."}, {"Citation": "Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci. 1985;82:4245-9."}, {"Citation": "Goedert M, Spillantini M, Crowther R. Tau proteins and neurofibrillary degeneration. Brain Pathol. 1991;1:279-86."}, {"Citation": "Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013;6:19-33."}, {"Citation": "De Leon M, George A, Golomb J, Tarshish C, Convit A, Kluger A, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging. 1997;18:1-11."}, {"Citation": "Anand A, Patience AA, Sharma N, Khurana N. The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review. Eur J Pharmacol. 2017;815:364-75."}, {"Citation": "Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:1179573520907397."}, {"Citation": "Thakur AK, Kamboj P, Goswami K, Ahuja K. Pathophysiology and management of Alzheimer's disease: an overview. J Anal Pharm Res. 2018;7:226-35."}, {"Citation": "Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol. 2014;5:37."}, {"Citation": "Ram\u00edrez BG, Bl\u00e1zquez C, del Pulgar TG, Guzm\u00e1n M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25:1904-13."}, {"Citation": "Solas M, Francis PT, Franco R, Ramirez MJ. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging. 2013;34:805-8."}, {"Citation": "Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, Walker MJ, et al. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis. 2009;8:1-6."}, {"Citation": "Volicer L, Stelly M, Morris J, McLAUGHLIN J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:913-9."}, {"Citation": "Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22:415-9."}, {"Citation": "Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23:116-7."}, {"Citation": "Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185:524-8."}, {"Citation": "Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J Alzheimers Dis. 2016;51:15-9."}, {"Citation": "Milton NG. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-\u03b2 peptide. Neurosci Lett. 2002;332:127-30."}, {"Citation": "Chen X, Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against \u03b2-amyloid insults. Neuroscience. 2011;178:159-68."}, {"Citation": "Harvey BS, Ohlsson KS, M\u00e5\u00e5g JL, Musgrave IF, Smid SD. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-\u03b2 evoked neurotoxicity in vitro. Neurotoxicology. 2012;33:138-46."}, {"Citation": "Janefjord E, M\u00e5\u00e5g JL, Harvey BS, Smid SD. Cannabinoid effects on \u03b2 amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol. 2014;34:31-42."}, {"Citation": "Van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, Filippis DD, et al. Endocannabinoids and \u03b2-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006;63:1410-24."}, {"Citation": "Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on \u03b2-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89:134-41."}, {"Citation": "Aso E, Palomer E, Juv\u00e9s S, Maldonado R, Mu\u00f1oz FJ, Ferrer I. CB 1 agonist ACEA protects neurons and reduces the cognitive impairment of A\u03b2PP/PS1 mice. J Alzheimers Dis. 2012;30:439-59."}, {"Citation": "Mart\u00edn-Moreno AM, Reigada D, Ram\u00edrez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol. 2011;79:964-73."}, {"Citation": "Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway. Neuropharmacology. 2012;63:653-66."}, {"Citation": "Haghani M, Shabani M, Javan M, Motamedi F, Janahmadi M. CB1 cannabinoid receptor activation rescues amyloid \u03b2-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell Physiol Biochem. 2012;29:391-406."}, {"Citation": "Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol Aging. 2013;34:791-804."}, {"Citation": "Mart\u00edn-Moreno AM, Brera B, Spuch C, Carro E, Garc\u00eda-Garc\u00eda L, Delgado M, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers \u03b2-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:1-15."}, {"Citation": "Aso E, Juv\u00e9s S, Maldonado R, Ferrer I. CB 2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A\u03b2PP/PS1 mice. J Alzheimers Dis. 2013;35:847-58."}, {"Citation": "Tol\u00f3n RM, N\u00fa\u00f1ez E, Pazos MR, Benito C, Castillo AI, Mart\u00ednez-Orgado JA, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009;1283:148-54."}, {"Citation": "Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol Cell Neurosci. 2013;56:255-62."}, {"Citation": "Chen R, Zhang J, Fan N, Teng Z-q, Wu Y, Yang H, et al. \u03949-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell. 2013;155:1154-65."}, {"Citation": "Scuderi C, Steardo L, Esposito G. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPAR\u03b3 involvement. Phytother Res. 2014;28:1007-13."}, {"Citation": "Aso E, S\u00e1nchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I. Cannabis-based medicine reduces multiple pathological processes in A\u03b2PP/PS1 mice. J Alzheimers Dis. 2015;43:977-91."}, {"Citation": "Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, et al. The potential therapeutic effects of THC on Alzheimer's disease. J Alzheimers Dis. 2014;42:973-84."}, {"Citation": "Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits \u03b2-amyloid-induced tau protein hyperphosphorylation through Wnt/\u03b2-catenin pathway rescue in PC12 cells. J Mol Med. 2006;84:253-8."}, {"Citation": "Esposito G, De Filippis D, Steardo L, Scuderi C, Savani C, Cuomo V, et al. CB1 receptor selective activation inhibits \u03b2-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett. 2006;404:342-6."}, {"Citation": "Casarejos MJ, Perucho J, Gomez A, Munoz MP, Fernandez-Estevez M, Sagredo O, et al. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis. 2013;35:525-39."}, {"Citation": "Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, et al. Opposing control of cannabinoid receptor stimulation on amyloid-\u03b2-induced reactive gliosis: In vitro and in vivo evidence. J Pharmacol Exp Ther. 2007;322:1144-52."}, {"Citation": "Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM, et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 2012;1:617-23."}, {"Citation": "Khodadadi H, Salles \u00c9L, Jarrahi A, Costigliola V, Khan M, Yu JC, et al. Cannabidiol ameliorates cognitive function via regulation of IL-33 and TREM2 upregulation in a murine model of Alzheimer's disease. J Alzheimers Dis. 2021;80:973-7."}, {"Citation": "Pihlaja R, Takkinen J, Eskola O, Vasara J, L\u00f3pez-Pic\u00f3n FR, Haaparanta-Solin M, et al. Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. J Neuroinflammation. 2015;12:1-6."}, {"Citation": "Elmazoglu Z, Rangel-L\u00f3pez E, Medina-Campos ON, Pedraza-Chaverri J, T\u00fanez I, Aschner M, et al. Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+ A\u03b21-42 peptide in rat hippocampal neurons. Neurochem Int. 2020;140:104817."}, {"Citation": "Hampson A, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (\u2212) \u03949-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci. 1998;95:8268-73."}, {"Citation": "Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana a. Ann N Y Acad Sci. 2000;899:274-82."}, {"Citation": "Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, et al. Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS One. 2011;6:e28668."}, {"Citation": "Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun. 2007;364:131-7."}, {"Citation": "Eubanks LM, Rogers CJ, Beuscher AE IV, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm. 2006;3:773-7."}, {"Citation": "Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci. 1989;86:9584-7."}, {"Citation": "Eshhar N, Striem S, Biegon A. HU-211, a nonpsychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport. 1993;5:237-40."}, {"Citation": "Nadler V, Mechoulam R, Sokolovsky M. The non-psychotropic cannabinoid (+)-(3\u2009S, 4\u2009S)-7-hydroxy-\u03946-tetrahydrocannabinol 1, 1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett. 1993;162:43-5."}, {"Citation": "Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci. 1992;89:3825-9."}, {"Citation": "Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78:43-50."}, {"Citation": "Zhuang S-Y, Bridges D, Grigorenko E, McCloud S, Boon A, Hampson RE, et al. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology. 2005;48:1086-96."}, {"Citation": "Noonan J, Tanveer R, Klompas A, Gowran A, McKiernan J, Campbell VA. Endocannabinoids prevent \u03b2-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem. 2010;285:38543-54."}, {"Citation": "Tanveer R, Gowran A, Noonan J, Keating SE, Bowie AG, Campbell VA. The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-\u03b2 and in the cortex of aged rats. J Biol Chem. 2012;287:34709-21."}, {"Citation": "Suliman NA, Taib CNM, Moklas MAM, Basir R. Delta-9-tetrahydrocannabinol (\u2206 9-THC) induce neurogenesis and improve cognitive performances of male Sprague dawley rats. Neurotox Res. 2018;33:402-11."}, {"Citation": "Marsicano G, Lafen\u00eatre P. Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci. 2009;1:201-30."}, {"Citation": "Ellis EF, Moore SF, Willoughby KA. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol. 1995;269:H1859-64."}, {"Citation": "Wagner JA, J\u00e1rai Z, B\u00e1tkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol. 2001;423:203-10."}, {"Citation": "Pacher P, Batkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Cannabinoids. 2005;168:599-625."}, {"Citation": "Iring A, Ruisanchez \u00c9, Leszl-Ishiguro M, Horv\u00e1th B, Benk\u0151 R, Lacza Z, et al. Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One. 2013;8:e53390."}, {"Citation": "Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fern\u00e1ndez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005;19:96-107."}, {"Citation": "Garc\u00eda-Arencibia M, Gonz\u00e1lez S, de Lago E, Ramos JA, Mechoulam R, Fern\u00e1ndez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134:162-70."}, {"Citation": "Garc\u00eda C, Palomo-Garo C, Garc\u00eda-Arencibia M, Ramos J, Pertwee R, Fern\u00e1ndez-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid \u03949-THCV in animal models of Parkinson's disease. Br J Pharmacol. 2011;163:1495-506."}, {"Citation": "Santos NAG, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RHC, et al. The neuroprotection of cannabidiol against MPP+-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. Toxicol In Vitro. 2015;30:231-40."}, {"Citation": "Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, et al. Effects of cannabinoids \u0394 (9)-tetrahydrocannabinol, \u0394 (9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. Phytomedicine. 2012;19:819-24."}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2022", "Month": "9", "Day": "12"}, {"Year": "2022", "Month": "12", "Day": "29"}, {"Year": "2023", "Month": "6", "Day": "8", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "1", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "13", "Hour": "11", "Minute": "53"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36637897", "10.1002/biof.1936"]}}], "PubmedBookArticle": []}